Health tech company Novo Nordisk (NVO) began rolling out the first GLP-1 pill for obesity in the United States on Monday. The launch marks the first oral option in a market long dominated by weekly injections.

The drug is sold under the Wegovy name and is priced for cash-paying patients between $149 and $299 per month. Pricing varies by dose, placing the pill among the lowest-cost GLP-1 options available.

U.S. regulators cleared the oral treatment about two weeks before the launch. The pill uses the same active ingredient, semaglutide, as Novo Nordisk’s injectable Wegovy.

The starting 1.5 milligram dose is available at more than 70,000 pharmacies nationwide. Retailers include CVS and Costco, along with select telehealth providers such as Ro, LifeMD, Weight Watchers, GoodRx, and Novo Nordisk’s NovoCare Pharmacy.

Higher doses are expected to reach patients by the end of the week. Cash-paying patients can obtain the starting dose for $149 per month.

The 4 milligram dose will also cost $149 per month through April 15, after which the price will rise to $199 per month. The highest doses, 9 milligrams and 25 milligrams, will be priced at $299 per month.

Patients with insurance coverage may pay as little as $25 per month. Cash-paying patients can also access the starting dose through President Donald Trump’s direct-to-consumer website, TrumpRx, under an agreement reached in November. The site is expected to launch in January, though timing remains unclear.

Injectable GLP-1 drugs from Novo Nordisk and Eli Lilly list at about $1,000 per month. Both companies offer lower cash prices for injections, generally ranging from $299 to $499.

The Food and Drug Administration also approved the pill to reduce the risk of major cardiovascular events in adults with obesity and established cardiovascular disease. Patients must wait 30 minutes before eating or drinking after taking the pill.

In a phase three trial of more than 300 adults with obesity and no diabetes, the highest dose produced average weight loss of up to 16.6% after 64 weeks. Eli Lilly is awaiting a regulatory decision on its own oral GLP-1 treatment later this year.